Shanghai Junshi Biosciences Reports Strong H1 2025 Results and R&D Advances

Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an announcement.

Shanghai Junshi Biosciences Co., Ltd. reported a significant increase in revenue and a reduction in losses for the first half of 2025, driven by strong domestic sales of its core product, TUOYI. The company also achieved notable progress in its R&D efforts, expanding its innovative pipeline and securing regulatory approvals for key products, which positions it well for future growth and international development.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the research, development, and commercialization of innovative therapies and drugs. The company operates in various therapeutic areas, including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases, and infectious diseases, with a diverse pipeline that includes monoclonal antibodies, small molecules, and vaccines.

Average Trading Volume: 13,773,473

Technical Sentiment Signal: Buy

Current Market Cap: HK$48.06B

Learn more about 1877 stock on TipRanks’ Stock Analysis page.